Terns Pharmaceuticals, Inc.
TERNCIK 0001831363 · Every Form 4 filed by insiders at this issuer. See financials →
Annual report (10-K)
Latest 10-K/A filed Apr 27, 2026. Sentiment + YoY language diff vs prior year. Read sections →
Signal:NeutralFull-doc fallback
Full filing:tone -0.0033
Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.
Recent 8-K announcements
Per-item disclosure feed. Item 2.02 is the earnings release.
Top insiders
Most active reporters at Terns Pharmaceuticals, Inc.
| Name | Roles | Filings |
|---|---|---|
| Kindler Jeffrey B | Director | 8 |
| Lu Hongbo | Director | 7 |
| Tripuraneni Radhika | Director | 7 |
| Yoon Seokho Bryan | Officer | 7 |
| Gordon Carl L | Director10% Owner | 5 |
Top performers
Insiders ranked by realized 90-day signed return on their open-market trades at Terns Pharmaceuticals, Inc.. Minimum 3 scored trades. Returns are signed - a sale followed by a rally counts against the insider.
| # | Insider | Trades | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|---|
| 1 | Gengos Andrew | 5 | 100% | +90.0% | +91.8% | +94.3% | +77.8% |
| 2 | Vignola Mark J. | 8 | 88% | +48.3% | +48.7% | +145.7% | -48.2% |
| 3 | Yoon Seokho Bryan | 5 | 80% | +44.8% | +30.4% | +145.7% | -48.2% |
| 4 | Sundaram Senthil Vel | 3 | 67% | +42.6% | +30.4% | +145.7% | -48.2% |
| 5 | Gordon Carl L | 6 | 100% | +22.6% | +22.6% | +23.7% | +21.4% |
| 6 | Orbimed Advisors LLC | 6 | 100% | +22.6% | +22.6% | +23.7% | +21.4% |
| 7 | Orbimed Advisors III Ltd | 6 | 100% | +22.6% | +22.6% | +23.7% | +21.4% |
| 8 | Orbimed Asia Gp III, L.P. | 6 | 100% | +22.6% | +22.6% | +23.7% | +21.4% |
| 9 | Orbimed Capital Gp VII LLC | 6 | 100% | +22.6% | +22.6% | +23.7% | +21.4% |
| 10 | Orbimed Genesis Gp LLC | 6 | 100% | +22.6% | +22.6% | +23.7% | +21.4% |
All filings
111 Form 4 / 4-A filings, newest first
| Filed | Top transaction | Shares | Price | Value | ||
|---|---|---|---|---|---|---|